Inflammatory bowel disease revisited: Newer drugs

S. B. Hanauer*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


The development of new drug therapy is an evolutionary process progressing from clinical success with current treatments through an understanding of interactions in the immune and inflammatory events that culminate in the tissue injury of IBD. The basic immunoinflammatory response is reviewed, with identification of the recognized and potential sites of activity of current therapies. Potential sites and implications for future interventions by newer therapies are discussed as we anticipate the discovery of the etiology and eventual cure for ulcerative colitis and Crohn's disease.

Original languageEnglish (US)
Pages (from-to)97-106
Number of pages10
JournalScandinavian Journal of Gastroenterology
Issue numberS175
StatePublished - 1990


  • 5-Aminosalicylic acid
  • Corticosteroids
  • Crohn's disease
  • Cyclosporin
  • Eicosanoids
  • Immunosuppressants
  • Inflammatory bowel disease
  • Methotrexate
  • Sulfasalazine
  • Ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Inflammatory bowel disease revisited: Newer drugs'. Together they form a unique fingerprint.

Cite this